BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.84 per share, missing estimates of -$0.69 by $0.15. The company also reported revenue of $194,520,000, beating estimates of $181,495,933 by $13,024,067.
Stock price change since market close: +2.3%
You can see Quiver Quantitative's $BBIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BRIDGEBIO PHARMA Insider Trading Activity
BRIDGEBIO PHARMA insiders have traded $BBIO stock on the open market 94 times in the past 6 months. Of those trades, 0 have been purchases and 94 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 74 sales selling 564,220 shares for an estimated $40,118,112.
- ANDREW LO has made 0 purchases and 4 sales selling 95,599 shares for an estimated $6,319,662.
- ANDREA ELLIS sold 64,921 shares for an estimated $4,211,301
- RONALD J DANIELS sold 61,031 shares for an estimated $3,888,999
- HANNAH VALANTINE has made 0 purchases and 2 sales selling 34,155 shares for an estimated $2,308,039.
- THOMAS TRIMARCHI (President and CFO) has made 0 purchases and 4 sales selling 30,534 shares for an estimated $2,141,551.
- RANDAL W. SCOTT has made 0 purchases and 5 sales selling 20,000 shares for an estimated $1,421,021.
- MARICEL APULI (Chief Accounting Officer) has made 0 purchases and 3 sales selling 4,510 shares for an estimated $329,578.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
BRIDGEBIO PHARMA Hedge Fund Activity
We have seen 238 institutional investors add shares of BRIDGEBIO PHARMA stock to their portfolio, and 197 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,261,181 shares (+144.2%) to their portfolio in Q4 2025, for an estimated $172,957,734
- JANUS HENDERSON GROUP PLC added 2,259,378 shares (+25.8%) to their portfolio in Q4 2025, for an estimated $172,819,823
- MACQUARIE GROUP LTD removed 1,933,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $147,862,513
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,602,036 shares (-78.0%) from their portfolio in Q4 2025, for an estimated $122,539,733
- VIKING GLOBAL INVESTORS LP removed 1,583,915 shares (-9.9%) from their portfolio in Q4 2025, for an estimated $121,153,658
- WELLINGTON MANAGEMENT GROUP LLP added 1,329,537 shares (+130.4%) to their portfolio in Q4 2025, for an estimated $101,696,285
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,051,679 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $80,442,926
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
BRIDGEBIO PHARMA Congressional Stock Trading
Members of Congress have traded $BBIO stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 3 purchases worth up to $45,000 on 03/19, 03/18, 03/03 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
BRIDGEBIO PHARMA Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 03/10/2026
- Barclays issued a "Overweight" rating on 01/28/2026
- Truist Securities issued a "Buy" rating on 01/08/2026
- Morgan Stanley issued a "Overweight" rating on 01/06/2026
To track analyst ratings and price targets for BRIDGEBIO PHARMA, check out Quiver Quantitative's $BBIO forecast page.
BRIDGEBIO PHARMA Price Targets
Multiple analysts have issued price targets for $BBIO recently. We have seen 12 analysts offer price targets for $BBIO in the last 6 months, with a median target of $98.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $100.0 on 04/29/2026
- Danielle Brill from Truist Securities set a target price of $102.0 on 04/29/2026
- Salim Syed from Mizuho set a target price of $106.0 on 04/28/2026
- Luca Issi from RBC Capital set a target price of $100.0 on 04/09/2026
- Anupam Rama from JP Morgan set a target price of $94.0 on 03/10/2026
- Trevor Allred from Oppenheimer set a target price of $81.0 on 02/25/2026
- Sean Laaman from Morgan Stanley set a target price of $98.0 on 02/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
